A new drug targeted at preventing the recurrence of liver cancer after it is treated surgically is expected to receive approval in most Asian countries by 2015, according to the company authorized to develop, produce and market the drug.
(Full text of the story is now in CNA English news archive. To view the full story, you will need to be a subscribed member of the CNA archive. To subscribe, please read here.)
Latest
- Politics
KMT defends funding allocation law revisions following DPP outcry
12/23/2024 05:40 PM - Business
Taiwan shares soar almost 600 points after U.S. rally
12/23/2024 04:51 PM - Politics
99% of 1-year conscripts passed required tests: Executive Yuan
12/23/2024 04:47 PM - Politics
Cabinet warns allocation amendments entail 'complete overhaul' of budget
12/23/2024 04:42 PM - Business
U.S. dollar closes lower on Taipei forex market
12/23/2024 04:36 PM